Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICOL, ALEXANDER W | 1 | 42.0% | +44.9% |
| POPA, ILEANA | 1 | 21.0% | +14.9% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.5% | +36.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 22d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16802678 | GENE THERAPY COMPOSITION FOR USE IN DIABETES TREATMENT | DACE DENITO, ALEXANDRA GERALDINE | 17d overdue |
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 22d |
| 17999717 | Fibroblast growth factor 21 (FGF21) gene therapy for improved muscle function | NICOL, ALEXANDER W | 56d |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1633 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17999717 | Fibroblast growth factor 21 (FGF21) gene therapy for improved muscle function | NICOL, ALEXANDER W | 1634 | §102 | Final Rejection | 56d | Pending | Nov 23, 2022 |
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 1633 | §103 | Final Rejection | 22d | Pending | Mar 02, 2021 |
| 16802678 | GENE THERAPY COMPOSITION FOR USE IN DIABETES TREATMENT | DACE DENITO, ALEXANDRA GERALDINE | 1636 | Other | Final Rejection | 17d overdue | Pending | Feb 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial